Literature DB >> 10945293

Immunohistochemical analysis of cyclin A, cyclin D1 and P53 in mammary tumors, squamous cell carcinomas and basal cell tumors of dogs and cats.

Y Murakami1, S Tateyama, A Rungsipipat, K Uchida, R Yamaguchi.   

Abstract

The involvement of cyclin A, cyclin D1 and p53 proteins in canine and feline tumorigenesis was analyzed immunohistochemically. In the present study, a total of 176 cases were examined, among which there were 108 canine cases (75 mammary lesions, 16 squamous cell carcinomas and 17 basal cell tumors) and 68 feline cases (43 mammary lesions, 20 squamous cell carcinomas and 5 basal cell tumors). Speckled nuclear staining for cyclin A was observed in 19/38 (50%) canine malignant mammary tumors and 18/37 (48.6%) feline mammary carcinomas, while this was not seen in benign mammary tumors of either dogs or cats. Marked intense nuclear cyclin A staining was seen in 7/16 (43.8%) canine squamous cell carcinomas and 18/20 (90.0%) feline squamous cell carcinomas. Only 3/17 (17.6%) canine basal cell tumors showed slight and scattered staining for cyclin A. Expression of cyclin D1 was very rare in both canine and feline tumors. Nuclear staining of p53 was found in 7/37 (18.9%) feline mammary carcinomas. Intense immunoreactivity for p53 was found in 6/16 (37.5%) canine squamous cell carcinomas and 8/20 (40%) feline squamous cell carcinomas. These results suggest that cyclin A may have a role in the proliferation of canine malignant mammary tumors, feline mammary carcinomas and squamous cell carcinomas of dogs and cats, and p53 may associate with the tumorigenesis of feline mammary carcinomas and squamous cell carcinomas of dogs and cats.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10945293     DOI: 10.1292/jvms.62.743

Source DB:  PubMed          Journal:  J Vet Med Sci        ISSN: 0916-7250            Impact factor:   1.267


  7 in total

1.  Immunophenotypic Characterization of Canine Splenic Follicular-Derived B-Cell Lymphoma.

Authors:  Leah Stein; Cynthia Bacmeister; Kris Ylaya; Patricia Fetsch; Zengfeng Wang; Stephen M Hewitt; Matti Kiupel
Journal:  Vet Pathol       Date:  2019-01-13       Impact factor: 2.221

2.  Quantitative Expression and Co-Localization of Wnt Signalling Related Proteins in Feline Squamous Cell Carcinoma.

Authors:  Antonio Giuliano; Rebecca Swift; Callum Arthurs; Georgina Marote; Francesca Abramo; Jenny McKay; Calum Thomson; Mariana Beltran; Michael Millar; Simon Priestnall; Jane Dobson; Fernando Costantino-Casas; Terry Petrou; Imelda M McGonnell; Anthony J Davies; Malcolm Weetman; Oliver A Garden; John R Masters; Christopher Thrasivoulou; Aamir Ahmed
Journal:  PLoS One       Date:  2016-08-25       Impact factor: 3.240

3.  Evaluation of expression of the Wnt signaling components in canine mammary tumors via RT2 Profiler PCR Array and immunochemistry assays.

Authors:  Fang Yu; Roberta Rasotto; Hong Zhang; Shimin Pei; Bin Zhou; Xu Yang; Yipeng Jin; Di Zhang; Degui Lin
Journal:  J Vet Sci       Date:  2017-09-30       Impact factor: 1.672

4.  Felis catus papillomavirus type-2 E6 binds to E6AP, promotes E6AP/p53 binding and enhances p53 proteasomal degradation.

Authors:  Gennaro Altamura; Karen Power; Manuela Martano; Barbara Degli Uberti; Giorgio Galiero; Giovanna De Luca; Paola Maiolino; Giuseppe Borzacchiello
Journal:  Sci Rep       Date:  2018-12-03       Impact factor: 4.379

5.  Gene expression association study in feline mammary carcinomas.

Authors:  Daniela Ferreira; Bárbara Martins; Maria Soares; Jorge Correia; Filomena Adega; Fernando Ferreira; Raquel Chaves
Journal:  PLoS One       Date:  2019-08-28       Impact factor: 3.240

6.  Does immunohistochemical staining of P53, Ki 67 and cyclin A accurately predict Wilms tumor recurrence and survival?

Authors:  Ahmed M Atwa; Ashraf T Hafez; Mohamed Abdelhameed; Mohamed Dawaba; Adel Nabeeh; Tamer E Helmy
Journal:  Arab J Urol       Date:  2022-04-11

Review 7.  DNA damage response proteins in canine cancer as potential research targets in comparative oncology.

Authors:  Beatriz Hernández-Suárez; David A Gillespie; Aleksandra Pawlak
Journal:  Vet Comp Oncol       Date:  2022-01-10       Impact factor: 2.385

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.